Izumi Hamada, PharmD, MS

Senior Research Investigator
Bristol Myers Squibb

Poster(s):

• (S-047) Population Pharmacokinetics and Exposure-Response Analysis of Nivolumab in Combination with Ipilimumab in Participants with First-Line Unresectable or Advanced Hepatocellular Carcinoma to Support Benefit-Risk Assessment
  Sunday, October 19, 2025

  7:00 AM - 5:00 PM MDT